Table 1 Patient characteristics according to TP53 status
From: WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma
Variable | TP53wild-type | TP53mutant | p-value |
|---|---|---|---|
N | 261/314 (83.1%) | 53/314 (16.9%) | Â |
Age (median, range) | 9.0 (5.0 – 18.5) | 10.0 (5.0 – 17.0) | p = 0.4 |
Gender (male) | 154/261 (59%) | 25/53 (47.2%) | p = 0.1 |
Histology | Â | Â | Â |
LCA | 31/261 (11.9%) | 23/53 (43.4%) | p = 0.0001* |
Classic | 204/261 (78.2%) | 25/53 (47.1%) | Â |
Desmoplastic/nodular | 21/261 (8.0%) | 2/53 (3.8%) | Â |
Missing | 5 /261 (1.9%) | 3/53 (5.7%) | Â |
M+ disease | 80/261 (30.7%) | 7/53 (13.2%) | p = 0.01 |
Subgroups | Â | Â | Â |
WNT | 72/261 (27.6%) | 15/53 (28.3%) | p = 0.003** |
SHH | 59/261 (22.6%) | 36/53 (67.9%) | Â |
Group 3 | 37/261 (14.2%) | 0/53 (0%) | Â |
Group 4 | 92/261 (35.2%) | 1/53 (1.9%) | Â |
Missing | 1/261 (0.4%) | 1/53 (1.9%) | Â |
Death | 54/261 (20.7%) | 24/53 (45.3%) | Â |
WNT | 5/72 (6.9%) | 0/15 (0%) | p = 0.004*** |
SHH | 9/59 (15.3%) | 24/36 (66.7%) | Â |